Vorinostat May Benefit Some Patients With Soft Tissue Sarcoma

Share this content:
A small subgroup of heavily pre-treated patients with soft tissue sarcoma may benefit from treatment with the histone deacetylase inhibitor vorinostat.
A small subgroup of heavily pre-treated patients with soft tissue sarcoma may benefit from treatment with the histone deacetylase inhibitor vorinostat.

A small subgroup of heavily pre-treated patients with soft tissue sarcoma may benefit from treatment with the histone deacetylase inhibitor (HDAC) vorinostat, a study published in the European Journal of Cancer has shown.1

Preclinical trials have demonstrated potential activity of vorinostat in soft tissue sarcoma; researchers therefore conducted this multicenter, open-label, phase 2 trial, for which 40 patients with locally advanced or metastatic soft tissue sarcoma who failed first-line anthracycline-based chemotherapy were enrolled. Of those, 20%, 25%, and 55% had received 1, 2, and 3 or more prior lines of therapy, respectively.

All participants received vorinostat 400 mg orally daily for 28 days of each 5-week cycles. Restaging of disease was performed every 3 cycles or at the time of clinical progression.

The best response after 3 cycles of vorinostat therapy was stable disease, which was observed in 23% of patients. Median progression-free survival and overall survival were 3.2 months and 12.3 months, respectively. Six patients demonstrated long-lasting disease stabilization for up to 10 cycles, though analyses were unable to identify baseline predictive markers in this small subgroup.

RELATED: Droplet Digital PCR Promising for Detecting Recurrent Ewing Sarcoma

Some grade 3 or higher toxicities were observed: 15% experienced hematologic toxicity, 13% had gastrointestinal disorders, 10% reported fatigue, 10% reported musculoskeletal pain, and 5% had pneumonia.

Further studies are warranted to identify predictive markers for treatment response to vorinostat, and vorinostat should be evaluated in combination with other agents in this difficult-to-treat patient population.                   

Reference

  1. Schmitt T, Mayer-Steinacker R, Mayer F, et al. Vorinostat in refractory soft tissue sarcomas – Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). Eur J Cancer. 2016. [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters